IBO · Impact Biomedical Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0K | - | $18.0K | $7.0K | - | - | - | - | - | - |
| Cost of Revenue | - | - | $1.0K | $11.0K | - | - | - | - | - | - |
| Gross Profit | - | - | $17.0K | ($4.0K) | - | - | - | - | - | - |
| R&D | $46.0K | - | $52.0K | $121.0K | $103.0K | - | $82.0K | - | $50.0K | - |
| SG&A | $1.62M | - | $261.0K | $246.0K | $248.0K | - | $132.0K | $145.0K | $148.0K | - |
| Total Operating Expenses | $1.01M | - | $1.13M | $1.16M | $1.01M | - | $1.13M | $1.01M | $771.0K | - |
| D&A | $285.0K | - | $288.0K | $288.0K | $283.0K | - | $281.0K | $279.0K | $280.0K | - |
| Operating Income | ($2.29M) | - | ($948.0K) | ($1.15M) | ($1.01M) | - | ($1.13M) | ($626.0K) | ($771.0K) | - |
| Interest Expense | $271.0K | - | $262.0K | $260.0K | $271.0K | - | $305.0K | $261.0K | $230.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.29M) | - | ($1.47M) | ($14.35M) | ($1.27M) | - | $4.25M | ($889.0K) | ($998.0K) | - |
| EPS - Basic | ($0.02) | - | ($0.12) | ($1.18) | ($0.11) | - | $0.37 | ($0.09) | ($0.10) | - |
| EPS - Diluted | ($0.02) | - | ($0.12) | ($1.18) | ($0.11) | - | $0.06 | ($0.09) | ($0.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.0K | $3.0K | $12.0K | $624.0K | $1.32M | $2.00M | $2.67M | $2.0K | $2.0K | $1.0K |
| Accounts Receivable | - | $5.0K | $15.0K | $200.0K | $4.0K | - | - | $128.0K | $128.0K | - |
| Inventory | $63.0K | $63.0K | $485.0K | $486.0K | $489.0K | - | - | - | - | - |
| Accounts Payable | $374.0K | $347.0K | $576.0K | $554.0K | $615.0K | $713.0K | $1.00M | $986.0K | $1.02M | $832.0K |
| Current Assets | $377.0K | $411.0K | $917.0K | $1.48M | $2.18M | $2.45M | $3.17M | $307.0K | $335.0K | $332.0K |
| Total Assets | $17.09M | $17.41M | $18.21M | $19.06M | $20.05M | $20.29M | $46.70M | $44.12M | $44.36M | $44.63M |
| Current Liabilities | $1.69M | $1.16M | $23.79M | $23.17M | $9.97M | $9.79M | $1.14M | $14.50M | $13.86M | $13.14M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.38M | $1.85M | $27.06M | $26.44M | $13.24M | $13.05M | $12.34M | - | - | $16.37M |
| Stockholders' Equity | $11.46M | $12.61M | ($11.81M) | ($10.34M) | $3.84M | $4.26M | $31.35M | $23.37M | $24.26M | $25.22M |
| Retained Earnings | ($51.79M) | ($49.51M) | ($54.75M) | ($53.28M) | ($38.94M) | ($37.67M) | ($10.56M) | ($14.81M) | ($13.92M) | ($12.96M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($464.0K) | - | - | - | ($682.0K) | - | - | - | ($712.0K) | - |
| Investing Cash Flow | ($1.0K) | - | - | - | $1.0K | - | - | - | ($4.0K) | - |
| Financing Cash Flow | $482.0K | - | - | - | - | - | - | - | $713.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | 94.4% | -57.1% | - | - | - | - | - | - |
| Operating margin | -32700.0% | - | -5266.7% | -16471.4% | - | - | - | - | - | - |
| EBITDA margin | -28628.6% | - | -3666.7% | -12357.1% | - | - | - | - | - | - |
| Net margin | -32671.4% | - | -8166.7% | -204942.9% | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 657.1% | - | 288.9% | 1728.6% | - | - | - | - | - | - |
| SG&A / Revenue | 23142.9% | - | 1450.0% | 3514.3% | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.4% | - | -8.1% | -75.3% | -6.3% | - | 9.1% | -2.0% | -2.2% | - |
| Return on equity | -19.9% | - | 12.4% | 138.7% | -33.0% | - | 13.5% | -3.8% | -4.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.22 | 0.35 | 0.04 | 0.06 | 0.22 | 0.25 | 2.79 | 0.02 | 0.02 | 0.03 |
| Quick ratio | 0.19 | 0.30 | 0.02 | 0.04 | 0.17 | 0.25 | 2.79 | 0.02 | 0.02 | 0.03 |
| Cash ratio | 0.01 | 0.00 | 0.00 | 0.03 | 0.13 | 0.20 | 2.34 | 0.00 | 0.00 | 0.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -8.4x | - | -3.6x | -4.4x | -3.7x | - | -3.7x | -2.4x | -3.4x | - |
| Equity multiplier | 1.49 | 1.38 | -1.54 | -1.84 | 5.22 | 4.76 | 1.49 | 1.89 | 1.83 | 1.77 |
| Liabilities / Assets | 0.14 | 0.11 | 1.49 | 1.39 | 0.66 | 0.64 | 0.26 | - | - | 0.37 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | - | - | - | - | - | - |
| Inventory turnover | - | - | 0.00 | 0.02 | - | - | - | - | - | - |
| Days sales outstanding | - | - | 304d | 10429d | - | - | - | - | - | - |
| Days inventory outstanding | - | - | 177025d | 16126d | - | - | - | - | - | - |
| Days payable outstanding | - | - | 210240d | 18383d | - | - | - | - | - | - |
| Cash conversion cycle | - | - | -32911d | 8172d | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | 33.3x | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -126.6% | - | 15.9% | -84.2% | -31.0% | - | -4.5% | 37.9% | - | - |
| Net income growth (YoY) | -80.5% | - | - | -1513.7% | -27.0% | - | - | 20.7% | - | - |
| EPS growth (YoY) | 81.8% | - | - | -1211.1% | -10.0% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 198.3% | 196.1% | - | - | -84.2% | -83.1% | 18.2% | -15.4% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$32.0K totalBiotech Retail Sales$32.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing IMPACT BIOMEDICAL INC. against the 5 most active filers in the same SIC group.